Handelsavisen
prelaunch
Companies ›Healthcare ›1061.HK
10
1061.HK — HKEX Pharmaceuticals

Essex Bio-Technology Ltd

HK$2,92
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
4,32 %
Op margin
23,3 %
ROE
13,2 %
Net margin
17,5 %
Debt / equity
0,14
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Essex Bio-Technology Ltd is a biotechnology company focused on the development and commercialization of pharmaceutical products, primarily in the healthcare sector.

Business. Essex Bio-Technology Ltd (1061.HK) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the pharmaceuticals industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Hong Kong Stock Exchange.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
13,2 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1061.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1061.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Essex Bio-Technology Ltd (1061.HK) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the pharmaceuticals industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Hong Kong Stock Exchange.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Essex Bio-Technology Ltd maintains a strong liquidity position, with a current ratio of 2.11 and cash and equivalents amounting to HKD 782.73 million, indicating a solid ability to meet short-term obligations. The company's debt-to-equity ratio is 0.14, suggesting a conservative capital structure with limited leverage. The return on equity of 13.18% and return on assets of 9.11% reflect strong profitability relative to its equity and asset base.

    The company's profitability is evident from its gross profit of HKD 1.62 billion and operating income of HKD 422.64 million, which contribute to a net income of HKD 318.09 million. These figures indicate a healthy margin structure and efficient cost management. The return on equity and return on assets are in line with the industry's preferred metrics, suggesting that the company is performing at or above the industry median.

    Essex Bio-Technology Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn.

    The company's growth trajectory is supported by a strong operating cash flow of HKD 306.32 million and a free cash flow of HKD 132.01 million, which can be reinvested for future growth. The capital expenditure of HKD -174.61 million indicates a reduction in capital spending, which may be a strategic move to preserve cash.

    The risk assessment for Essex Bio-Technology Ltd indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash reserves further mitigate these risks. There is no indication of near-term dilution pressure, and the company's financial position supports its current operations without the need for additional equity issuance.

    Recent events, as reflected in the financial data, show a stable performance with a last actual EPS of 0.39 HKD and a last actual revenue of HKD 1.18 billion. These figures align with the company's reported financial results and suggest consistent performance.

    Key takeaways
    • Essex Bio-Technology Ltd has a strong liquidity position with a current ratio of 2.11 and significant cash reserves.
    • The company's profitability is robust, with a return on equity of 13.18% and a return on assets of 9.11%.
    • The company's capital structure is conservative, with a debt-to-equity ratio of 0.14.
    • Essex Bio-Technology Ltd's revenue is concentrated in a single segment, which may increase its exposure to market risks.
    • The company's operating and free cash flows are positive, supporting future growth and operational flexibility.
    • The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
    • **margin_outlook_rationale**: The company's strong gross profit and operating income suggest that margins are likely to remain stable or improve in the near term due to efficient cost management.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$2,92
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    HK$2.41B
    Net cashⓘ
    HK$435.8M
    Current ratioⓘ
    2.1
    Debt / equityⓘ
    0.1
    ROAⓘ
    9.1%
    ROEⓘ
    13.2%
    Cash conversionⓘ
    96.0%
    CapEx / revenueⓘ
    -9.6%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin23,3 %Above P75
    Net Margin17,5 %Above P75
    ROE13,2 %Above P75
    Capex / Rev-9,6 %Below median
    D/E0,14Above median
    Cash Conv0,96Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Essex Bio-Technology Ltd Market data — financials · 2026-05-26
    • Essex Bio-Technology Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Patrick NgiamExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1061.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage